In a study of 844,000 children and adolescents without prior COVID infection, vaccine effectiveness was approximately 61% in children and 67% in adolescents versus the delta variant, but only approximately 16% and 26%, respectively, versus omicron.

Some experts responded to the recently published study, stating that “These authors have been pushing back against treating COVID as airborne for 3 years,” and that the study “will be used to justify policies of supplying healthcare workers … with inadequate protection.”

The pandemic has caused doctors stress, financial loss, and other issues, (approximately 8% of doctors (representing about 16,000 practices) closed their doors in 2020), but physician dissatisfaction with the profession has been an issue for years. According to a 2018 survey, 54% of those polled were thinking about retiring in the next five years (including 30% of those under 50). Why? What are the primary reasons that so many doctors want to retire?

Spectrum Pharmaceuticals would need to study the drug further, including generating data from a randomized controlled trial, according to the release. Spectrum responded by stating that it would “de-prioritize poziotinib program activities, effective immediately.” The decision comes after the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously that the drug’s demonstrated clinical benefit did not outweigh its risks.

Most people would agree that a doctor’s behavior is unprofessional, arguably unethical, and certainly unacceptable when he or she uses the wrong treatment, whether willfully or through ignorance, or when they use the right treatment incorrectly. What, then, should we think about researchers who use the wrong techniques, use the right techniques wrongly, misinterpret their results, report their results selectively, cite the literature selectively, and draw unjustified conclusions?

In this video-supported CME activity, an expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.